Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Apr 14, 2009; 15(14): 1786-1787
Published online Apr 14, 2009. doi: 10.3748/wjg.15.1786
Published online Apr 14, 2009. doi: 10.3748/wjg.15.1786
Citation | Dara et al[1] | Jones et al[4] | Shim et al[3] | Stevens et al[2] | ||
Patient age (yr) | 40 | 33 | 19 | 28 | 27 | 30 |
Patient gender | F | F | M | M | M | M |
Reported symptoms/duration | Fatigue, nausea, vomiting, cramping, fever, chills, anorexia/3 d | Fatigue, nausea, cramping, abdominal pain/2 wk | Nausea, vomiting, jaundice/6 d | Fatigue, dyspnea on exertion, jaundice/ 3 wk | Fatigue, jaundice/8 d | Fatigue, vomiting, jaundice, fever/10 d |
Aspartate aminotransferase (U/L) | 1020 | 934 | 1981 | 1049 | 1808 | 59 |
Alanine aminotransferase (U/L) | 1150 | 570 | 1143 | 2272 | 3131 | 45 |
Serum alkaline phosphatase (U/L) | 299 | 112 | 153 | 153 | 171 | 530 |
Serum bilirubin (mg/L) | 6.7 | 209 | 117 | 181 | 78 | 78 |
Serum direct bilirubin (mg/L) | Not reported | 142 | 68 | 90 | Not reported | Not reported |
Prothrombin time (s) | Not reported | Not reported | 17.1 | 12.8 | 16 | 15 |
- Citation: Lobb A. Hepatoxicity associated with weight-loss supplements: A case for better post-marketing surveillance. World J Gastroenterol 2009; 15(14): 1786-1787
- URL: https://www.wjgnet.com/1007-9327/full/v15/i14/1786.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.1786